103 research outputs found
Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator. Correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction. The TAMI Study Group.
Systolic left ventricular function after reperfusion therapy for acute myocardial infarction. Analysis of determinants of improvement. The TAMI Study Group.
The safety of anistreplase from the placebo-controlled aims study (anistreplase intervention mortality study)
Impact of age on clinical outcome and postlytic management strategies in patients treated with intravenous thrombolytic therapy. Results from the TIMI II Study. TIMI II Investigators.
Dipyridamole echocardiography test. A new tool for detecting jeopardized myocardium after thrombolytic therapy.
Low-molecular-weight heparins in acute myocardial infarction: RationaLe and results of a pilot study
After correcting for worse baseline characteristics, women treated with thrombolytic therapy for acute myocardial infarction have the same mortality and morbidity as men except for a higher incidence of hemorrhagic stroke. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Study.
Effects of thrombolytic therapy administered 6 to 24 hours after myocardial infarction on the signal-averaged ECG. Results of a multicenter randomized trial. LATE Ancillary Study Investigators. Late Assessment of Thrombolytic Efficacy.
Thrombolytic Therapy Is Indicated for Patients Over 75 Years of Age With ST‐Elevation Acute Myocardial Infarction: Protagonist Viewpoint
- …